Literature DB >> 18809243

MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells.

Sai-Wen Tang1, Wen-Hsin Chang, Yih-Ching Su, Yu-Chi Chen, Yen-Han Lai, Pei-Tzu Wu, Chyong-Ing Hsu, Wei-Chou Lin, Ming-Kuen Lai, Jung-Yaw Lin.   

Abstract

Clear cell renal cell carcinoma (ccRCC) is the major and aggressive subtype of RCC. Previously, we identified 383 differentially expressed genes by analyzing full-length cDNA libraries of ccRCC and normal kidney tissues. In this study, we applied functional network analysis to the differentially expressed genes for identifying deregulated molecular pathways in ccRCC, and the results indicated that MYC showed a prominent role in the highest scoring network. The upregulation of MYC expression was validated in ccRCC tissues and cell lines. Furthermore, Knockdown of MYC expression by MYC-specific siRNA significantly inhibited the abilities of uncontrolled proliferation, anchorage-independent growth and arrested cell cycle in the G0/G1 phase in ccRCC cells. Moreover, we found that 37 differentially expressed genes were shown to be MYC-target genes, and the upregulation of the MYC-target genes BCL2, CCND1, PCNA, PGK1, and VEGFA were demonstrated. The expression of these MYC-target genes was significantly correlated with the expression of MYC in ccRCC tissues, and knockdown of MYC also suppressed the expression of these MYC-target genes in ccRCC cells. The recruitment of MYC to the promoter regions of BCL2, CCND1, PCNA, PGK1, and VEGFA was shown by Chromatin immunoprecipitation assay. These results suggest that MYC pathway is activated and plays an essential role in the proliferation of ccRCC cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18809243     DOI: 10.1016/j.canlet.2008.07.038

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  56 in total

1.  pVHL-mediated transcriptional repression of c-Myc by recruitment of histone deacetylases.

Authors:  In-Young Hwang; Jae-Seok Roe; Ja-Hwan Seol; Hwa-Ryeon Kim; Eun-Jung Cho; Hong-Duk Youn
Journal:  Mol Cells       Date:  2012-02       Impact factor: 5.034

2.  Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.

Authors:  Luciana Schultz; Alcides Chaux; Roula Albadine; Jessica Hicks; Jenny J Kim; Angelo M De Marzo; Mohamad E Allaf; Michael A Carducci; Ronald Rodriguez; Hans-Joerg Hammers; Pedram Argani; Victor E Reuter; George J Netto
Journal:  Am J Surg Pathol       Date:  2011-10       Impact factor: 6.394

3.  Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma.

Authors:  Nicole M White-Al Habeeb; Ashley Di Meo; Andreas Scorilas; Fabio Rotondo; Olena Masui; Annetta Seivwright; Manal Gabril; Andrew H A Girgis; Michael A Jewett; George M Yousef
Journal:  Clin Exp Metastasis       Date:  2015-06-03       Impact factor: 5.150

Review 4.  Oncometabolites in renal cancer.

Authors:  Cissy Yong; Grant D Stewart; Christian Frezza
Journal:  Nat Rev Nephrol       Date:  2019-10-21       Impact factor: 28.314

5.  Prognostic value of β-catenin, c-myc, and cyclin D1 expressions in patients with esophageal squamous cell carcinoma.

Authors:  Wei Wang; Lexun Xue; Pengju Wang
Journal:  Med Oncol       Date:  2010-02-09       Impact factor: 3.064

6.  MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism.

Authors:  Emelyn H Shroff; Livia S Eberlin; Vanessa M Dang; Arvin M Gouw; Meital Gabay; Stacey J Adam; David I Bellovin; Phuoc T Tran; William M Philbrick; Adolfo Garcia-Ocana; Stephanie C Casey; Yulin Li; Chi V Dang; Richard N Zare; Dean W Felsher
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-11       Impact factor: 11.205

Review 7.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

8.  A Comprehensive Study of Progressive Cytogenetic Alterations in Clear Cell Renal Cell Carcinoma and a New Model for ccRCC Tumorigenesis and Progression.

Authors:  Zhongfa Zhang; Bill Wondergem; Karl Dykema
Journal:  Adv Bioinformatics       Date:  2010-07-05

9.  Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1.

Authors:  Henry Zall; Arnim Weber; Robert Besch; Niko Zantl; Georg Häcker
Journal:  Mol Cancer       Date:  2010-06-24       Impact factor: 27.401

10.  Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study.

Authors:  A Ingels; M Hew; F Algaba; O J de Boer; R J A van Moorselaar; S Horenblas; P Zondervan; J J M C H de la Rosette; M Pilar Laguna Pes
Journal:  World J Urol       Date:  2016-05-20       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.